Daily Archives: January 18, 2018

Current therapies for inflammatory bowel disease (IBD) are aimed at immune suppression. These have not prevented disease progression for the majority of IBD patients and come with consequent risk. There is a recognized need for new, safe and effective … Continue reading →

A disturbed balance between reactivity and tolerance of the intestinal epithelium (IE) to bacterial compounds is one of the key contributors to the IBD pathogenesis. To date, research has mainly focused on the epithelial responses in general, whereas i… Continue reading →

Filgotinib (fil), a selective JAK1 inhibitor, has shown efficacy in a randomized double-blind, placebo (pbo)-controlled phase 2 study in Crohn’s disease (CD) (FITZROY [1]), which included centrally read endoscopy and histopathology assessments after … Continue reading →

Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) enhances neutrophil regulation of gut bacteria. Crohn’s Disease (CD) patients with reduced neutrophil GM-CSF signaling are more likely to experience stricturing complications requiring surgery… Continue reading →

Simultaneous analyses of peripheral and mucosal immune compartments can yield insight into the pathogenesis of mucosal-associated diseases. Although methods to preserve peripheral immune cells are well established, studies involving mucosal immune cell… Continue reading →

Studies have shown that physical activity has therapeutic effects on inflammatory bowel disease (IBD) by reducing disease activity, improving intestinal symptoms and positively impacting quality of life. In addition, exercise is helpful in offsetting p… Continue reading →

We have published data sets revealing the majority of FOXP3 gene targets in CD4+ lymphocytes isolated from Crohn’s lesions are significantly up-regulated. FOXP3 gene target status in the disease state is incongruent with FOXP3 and its associated comp… Continue reading →

For women with chronic inflammatory diseases, diagnosis and treatment initiation often overlap with peak reproductive years. High disease activity is associated with increased risk of pregnancy complications and adverse outcomes; disease control is imp… Continue reading →

Crohn’s disease treatment costs with certolizumab pegol (CZP) have been shown to be lower than infliximab (IFX), mainly due to lower CZP drug costs. Here, we examined the one-year (yr) all-cause healthcare resource utilization (HRU) and costs, incurr… Continue reading →

Data are emerging about the role of patient input on decision making for treatment of IBD. There are now multiple options for biologics when considering mechanism of action and means of administration. We sought to understand some of the disconnect bet… Continue reading →